Center for Medical Genomics Center for Medical Genomics Faculty of Medicine Ramathibodi Hospital Mahidol University The COVID-19 Situation Report said that although the World Health Organization (WHO) announced that globally there were 2.3 million new cases and nearly 15,000 deaths during the 28-day period (April 24 to May 21, 2023). There was a drop of 21% and 17% respectively compared to 28 days ago (March 27 to April 23). world health organization also warned that the highest death rate due to COVID-19 Currently found in Southeast Asia.
in Asia, especially China It is facing a new wave of COVID-19 infections from four subspecies of the Omicron XBB strain: XBB.1.5, XBB.1.16, XBB.1.9.1, and XBB.2.3. It has been increasing steadily since the end of April 2023 and from the calculations it is expected that the highest “peak” will be 65 million per week by the end of June 2023.
Report from Beijing on May 28, 2023 by Xinhua News Agency – Senior official Dr. Wang Liping of the China CDC said that COVID-19 infection Overall, in China, the prevalence has increased since mid-May 2023, with COVID-19 patients Most showed mild symptoms. by the number of patients receiving treatment at clinics and hospitals The overall number is still much lower than during the previous infection. And most patients have only mild symptoms.
Dr Wang said infections caused by the covid-19 sub-strain of the covid-19 strain XBB would persist for some time. But the overall situation remains stable and under control. It has little impact on the operation of medical and social services.
Another expert from the Chinese Department of Disease Control, Dr. Chen Chao, noted that from the monitoring data, The XBB substrain is now the predominant strain of COVID-19. In both imported infections and locally induced infections, no significant changes in both genomic and pathogenesis were observed.
Dr. Chen said China’s multi-channel early warning and surveillance system is highly effective. If any risk signal from the XBB group is detected, it can coordinate with disease control agencies across the country to immediately issue appropriate countermeasures in real time.
Dr. Li Tongsheng, chief physician of the department of respiratory and infectious diseases at Beijing Youan Hospital, Capital Medical University, said that in general, COVID-19 patients Re-infection shows fewer symptoms than initial infection. And clinical data shows that most reinfected people have mild sore throats and recover more quickly. The symptoms last for 3-5 days.
Outbreak of COVID-19 The new wave in China and ASEAN is driven by four subspecies of Omicron XBB, namely XBB.1.5, XBB.1.16, XBB.1.9.1, and XBB.2.3, which are prone to rapidly spreading infections. widely And in some people, symptoms may be severe despite being vaccinated or previously infected with COVID-19, so access to ready-made antiretrovirals and antibodies is important during this time.
The Medical Genome Center, Ramathibodi Hospital, has analyzed the entire genetic code of COVID-19. In the global COVID database “GISAID”, omicron XBB hybrids circulating in China were found. XBB.1.9.1(21%), XBB.1.16 (19%), XBB.188.8.131.52 or FL.2 (17%), XBB.1.5 (7%) and XBB.2.3*(2%).
While Thailand has omicron XBB hybrids circulating in the country consisting of XBB.1.16 (16%), XBB.1.9.1(11%), XBB.1.5 (10%), and XBB.2.3* (1%).
The World Health Organization (WHO) has classified the four subspecies of omicrons as follows:
– Omicron XBB.1.5 designated as a subspecies of interest (variant of interest: VOI).
– Omicron XBB.1.16 is designated as a subspecies under monitoring (Variant under Monitoring: VUM).
– Omicron XBB.1.9.1 designated as Variant under Monitoring (VUM)
– Omicron XBB.2.3 is designated as a subspecies under monitoring (Variant under Monitoring: VUM).
without deciding to upgrade any breed to become a breed of concern (variant of concern: VOC).
The Genome Center, Ramathibodi Hospital, analyzed data from the entire genome of the genetic code of COVID-19. From the samples of infected people in Thailand, it was found that
– Omicron XBB.1.16 has a relative growth advantage over XBB.1.5 by 42%.
-Omicron XBB.1.16 has a relative growth advantage over XBB.1.9.1 about 26%.
– Omicron XBB.1.9.1 has a relative growth advantage over XBB.1.5 about 8%.
– Omicron XBB.2.3 has a relative growth advantage over XBB.1.5 about 8%.
CR: Thank you for the information – picture.
#China #clarifies #strains #Omicron #XBB #severely #control #severe #assessed